Dicerna Pharmaceuticals Inc: directors' dealings · United States · SEC (Form 4)

About Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc. (ticker: DRNA) was a U.S.-based biopharmaceutical company previously listed on the NASDAQ, in the United States, and known for its focus on RNA interference, or RNAi. Founded in 2006, Dicerna was headquartered in Lexington, Massachusetts, and built its corporate identity around a proprietary RNAi platform called GalXC, designed to silence disease-causing genes. The company’s business model was typical of a specialty biotech: heavy R&D spending, a platform-led pipeline, and a focus on high-unmet-need indications rather than large-scale commercial franchises. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1399529/000139952920000009/a2019_drnax10k.htm?utm_source=openai)) Strategically, Dicerna’s core competence was not broad commercial manufacturing or diversified product sales, but the development of subcutaneously delivered RNAi therapeutics with potentially infrequent dosing. That feature was a key part of its competitive positioning, because it suggested a more convenient treatment profile for chronic diseases than some existing options. Over time, the company expanded its technological narrative from its liver-focused GalXC programs into GalXC-Plus, a newer evolution intended to broaden the application of its RNAi science across additional therapeutic areas. Its pipeline and partner-facing programs included rare diseases and liver-related diseases such as primary hyperoxaluria, hepatitis B, alpha-1 antitrypsin deficiency, and other genetically defined conditions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1399529/000139952921000042/drna-20201231.htm?utm_source=openai)) In competitive terms, Dicerna operated in a field dominated by better-capitalized RNAi leaders and large pharma partners. As a result, its value proposition was increasingly that of a technology platform and strategic asset rather than a standalone commercial growth story. That dynamic culminated in Novo Nordisk’s acquisition of Dicerna, completed in December 2021 for $38.25 per share in cash. After the transaction closed, Dicerna’s common stock was delisted from the NASDAQ Global Select Market, which is highly relevant for investors: DRNA is no longer an active listed equity today, even though it remains an important historical reference in the U.S. biotech space. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1399529/000119312521367447/d259099dex991.htm?utm_source=openai)) The most important recent corporate event, therefore, is the completed takeover by Novo Nordisk, which absorbed Dicerna’s RNAi technology into its broader rare disease and chronic disease strategy. Prior to that, Dicerna was a regular SEC filer, including Form 4 insider transaction disclosures, consistent with its status as a publicly traded U.S. issuer. For French-speaking investors, Dicerna is best understood as an innovation-driven biotechnology company founded in the United States, with a differentiated platform and a meaningful strategic exit rather than a continuing public-market equity story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1259856/000139952921000174/0001399529-21-000174-index.htm?utm_source=openai))